Abstract
Advanced systemic mastocytosis (AdvSM) is a group of rare disorders characterized by abnormal growth and accumulation of mast cells in one or several organs which lead to mediator release and/or organ dysfunction/damage with therefore reduced life expectancy. The study objective was to describe the distribution of systemic therapy prescriptions and prevalence of adult AdvSM patients in Germany based on claims data from 2015 to 2020. Avapritinib received EMA approval in March 2022 and was therefore not included in the analysis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
